Arbutus Biopharma FY 2025 net loss was USD 34 million, revenue rose 128% to USD 14 million

Reuters03-23
<a href="https://laohu8.com/S/ABUS">Arbutus Biopharma</a> FY 2025 net loss was USD 34 million, revenue rose 128% to USD 14 million
  • Arbutus published a fourth-quarter and full-year 2025 earnings release, reporting FY revenue of USD 14.1 million and a FY net loss of USD 33.5 million, or USD 0.17 per share.
  • FY revenue rose 128% to USD 14.1 million due to recognition of previously deferred revenue tied to the conclusion of the Qilu partnership, partly offset by lower license royalty revenue linked to a decline in Alnylam’s ONPATTRO sales.
  • Research and development expense fell 53.26% to USD 25.2 million as the company streamlined to focus on imdusiran and AB-101, including discontinuing discovery efforts and the IM-PROVE III trial.
  • General and administrative expense decreased 28.09% to USD 15.9 million, reflecting cost-cutting that reduced compensation-related costs and legal fees.
  • Cash, cash equivalents and marketable securities were USD 91.5 million at year-end 2025, and management said it is evaluating a return of capital in the third quarter of 2026 after receiving its portion of a USD 950 million noncontingent settlement payment from Moderna under an LNP litigation settlement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676121) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment